Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

Georgina V. Long, Sonia Dolfi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Leslie A. Fecher, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Caroline Gaudy-Marqueste, Emilio Murillo, Michele Maio, Maximilian Rohde, Charlie Garnett-Benson, Ruiyun Jiang, Bohang Chen, Jia Xin Yu, Travis Hollmann, Gabriele Zuchtriegel, Hussein Tawbi

Open source

DOI: 10.1038/s41591-026-04756-1
Published: 2026-10-24
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04756-1,
  title = {Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial},
  author = {Georgina V. Long and Sonia Dolfi and F. Stephen Hodi and Evan J. Lipson and Dirk Schadendorf and Paolo A. Ascierto and Luis Matamala and Erika Castillo Gutiérrez and Piotr Rutkowski and Helen J. Gogas and Leslie A. Fecher and Christopher D. Lao and Juliana Janoski De Menezes and Stéphane Dalle and Ana Arance and Caroline Gaudy-Marqueste and Emilio Murillo and Michele Maio and Maximilian Rohde and Charlie Garnett-Benson and Ruiyun Jiang and Bohang Chen and Jia Xin Yu and Travis Hollmann and Gabriele Zuchtriegel and Hussein Tawbi},
  year = {2026},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-026-04756-1},
  url = {https://doi.org/10.1038/s41591-026-04756-1}
}

RIS

TY  - JOUR
TI  - Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial
AU  - Georgina V. Long
AU  - Sonia Dolfi
AU  - F. Stephen Hodi
AU  - Evan J. Lipson
AU  - Dirk Schadendorf
AU  - Paolo A. Ascierto
AU  - Luis Matamala
AU  - Erika Castillo Gutiérrez
AU  - Piotr Rutkowski
AU  - Helen J. Gogas
AU  - Leslie A. Fecher
AU  - Christopher D. Lao
AU  - Juliana Janoski De Menezes
AU  - Stéphane Dalle
AU  - Ana Arance
AU  - Caroline Gaudy-Marqueste
AU  - Emilio Murillo
AU  - Michele Maio
AU  - Maximilian Rohde
AU  - Charlie Garnett-Benson
AU  - Ruiyun Jiang
AU  - Bohang Chen
AU  - Jia Xin Yu
AU  - Travis Hollmann
AU  - Gabriele Zuchtriegel
AU  - Hussein Tawbi
PY  - 2026
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04756-1
UR  - https://doi.org/10.1038/s41591-026-04756-1
ER  -

APA

Long, G. V., Dolfi, S., Hodi, F. S., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H. J., Fecher, L. A., Lao, C. D., Menezes, J. J. D., Dalle, S., Arance, A., Gaudy-Marqueste, C., Murillo, E., Maio, M., Rohde, M., Garnett-Benson, C., Jiang, R., Chen, B., Yu, J. X., Hollmann, T., Zuchtriegel, G., & Tawbi, H. (2026). Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04756-1

Source records

crossref · retrieved 2026-11-07T15:34:39.664Z